The British Association for Psychopharmacology developed an evidence-based consensus
guideline on the management of catatonia. A group of international experts from a wide …

Introduction Maintenance antipsychotic treatment improves multiple outcomes in people with
schizophrenia. These benefits are challenged by medication nonadherence, which is a …

BACKGROUND Catatonia is a complex psychomotor syndrome that often goes
unrecognized and untreated, even though its classification has evolved in recent years …

Neuroleptic malignant syndrome (NMS) is a rare but serious and sometimes fatal
complication in patients taking antipsychotic drugs, and its underlying mechanism still …

Clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS)
syndrome is a rare adverse reaction. We aimed to screen a large pharmacovigilance …

Objectives: Co-occurring substance use disorders (SUDs) among individuals with
schizophrenia are a prevalent and complex psychiatric comorbidity, which is associated with …

Catatonia occurs secondary to both primary psychiatric and neuromedical etiologies.
Emerging evidence suggests possible linkages between causes of catatonia and …

We hypothesized that shifting from oral second-generation antipsychotics (SGA) to their long-
acting injectable (LAI) counterpart would be beneficial for the psychopathological, cognitive …

Introduction: Antipsychotic drugs are the main therapy for schizophrenia and have been
widely used in mental disorder fields. However, the research on the safety of antipsychotic …

In the last few decades psychopharmacology has witnessed an incredible development in
terms of efficacy, safety and number of options available for the treatment and management …